76 ADAPTIVE SKIN CARE Erythema clinical response
100 80 60 40 20 0
Placebo Toleroxyl T14 Placebo ** Functional signs
120 100 80 60 40 20 0
Toleroxyl T28
Figure 6: Dermatological evaluation (physical signs) of erythema improvement. **p<0.01
inflammation. It re-educates how the skin responds to environmental stimuli, promoting immune tolerance, barrier resilience and recovery of skin homeostasis under chronic pollution exposure.
Clinical evaluation (in vivo) To confirm in vitro biological activity in human subjects, two independent, randomised, double-blind, placebo-controlled clinical studies were conducted in volunteers diagnosed with hyperreactive skin (sensitive, reactive and redness- prone, with clinical signs of discomfort) who spent a minimum of 16 hours per day indoors. Both studies used a twice-daily application protocol.
In vivo 1 Skin redness decrease
Inflammatory cytokines TNF-α Placebo ** **
Toleroxyl T14
Placebo
Toleroxyl T28
Figure 7: Dermatological evaluation of functional signs: burning, itching, stinging, and skin tightness. **p<0.01
The active statistically reduced skin redness up to -30% in only 14 days. The visual improvement across volunteers was consistent and progressive: Day 14 images show meaningful reduction in the area and intensity of redness, with continued improvement to Day 28 (Figure 5).
Dermatological evaluation Alongside the instrumental redness measurements, the study used a validated five-point clinical scale assessed by a qualified dermatologist, covering both physical signs (erythema) and functional signs of hyperreactive skin (burning, itching, stinging, and skin tightness). By Day 28, more than nine out of ten
volunteers in the treated group showed measurable clinical erythema improvement versus placebo. The placebo response remained
■ Placebo ■ Toleroxyl
modest and consistent throughout, confirming that the effect is attributable to the recombinant human protein (Figure 6). These findings are consistent with the
observed reductions in skin redness, supporting the robustness of the active’s efficacy in regulating and soothing skin immune responses in vivo, particularly in hyperreactive skin exposed to indoor contaminants. At Day 28, 100% of volunteers using the
biotech active also showed improvement across all four functional signs associated with sensitive skin versus placebo (Figure 7). These effects are attributed to its previously
demonstrated immunomodulatory activity and its role in reinforcing skin barrier function, making it a gentle yet effective option for protecting and soothing sensitive skin against commonly encountered indoor pollutants.
Clinical decrease in pro-inflammatory cytokines This section provides clinical evidence of the immune re-educating capacity of the active ingredient, demonstrating its ability to biochemically reduce inflammatory cytokines levels in the skin. To this end, samples from the stratum
IL-8
corneum were collected in vivo by tape stripping, and cytokine levels (TNF-α, IL-6 and IL-8) were quantified by ELISA. The consistent, directional reduction across
IL-6 -20 -15 -10 -5 % Variation vs T0 Figure 8: Pro-inflammatory cytokines reduction of the active versus placebo PERSONAL CARE MAGAZINE October 2026 0 5 10
all three cytokines demonstrates a genuine immunomodulatory effect in vivo, confirming that the tolerogenic mechanism characterised in vitro is operating in human skin under real-world conditions. The ingredient reduced skin reactivity
markers (IL-6: -4%; IL-8: -23%; TNF-α: -7% versus placebo), supporting a soothing effect on dermatologically assessed hyperreactive skin (Figure 8), improving skin tolerance to indoor environmental stressors.
www.personalcaremagazine.com
% of improved subjects
% of improved subjects
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
